

Propofol 1% (10mg/mg) emulsion of long and medium chain triglycerides (MCT-LCT) (Propofol Lipuro[®])
(No. 53/03)

B.Braun

Summary of Recommendation

12 January, 2004

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and ADTCs on its use in NHS Scotland. The recommendation is summarised as follows:

Advice: following a full submission.

Accepted for use within NHS Scotland

Propofol MCT-LCT emulsion 1% is a new formulation of an existing product. It is as effective as alternative formulations of propofol. Pain on injection is significantly reduced in frequency and intensity compared with alternative formulations, though not totally eliminated. The major advantage of this formulation will be realised when co-administration of lignocaine is unnecessary.

This advice is based on the assumption that the product will be available through contract at a price that is competitive with available formulations of propofol.

Professor David H Lawson
Chairman